The Center for Responsible Science joined a group of clinical trial participants in suing the FDA for denying a June 2014 citizen petition. Read More

Drugmakers submitting anonymous clinical data in applications to the European Medicines Agency must keep up on technology advances that could put that data at risk for re-identification. Read More

The International Committee of Medical Journal Editors is seeking feedback on proposed requirements involving transparency for clinical trials authors as a condition for publication in member journals. Read More

The pharmaceutical industry is becoming more active in sharing clinical trial data in a way that may have seemed inconceivable 20 years ago, drugmakers said, even as it has taken heat for being opaque on disclosures. Read More

Results were mixed for drugmakers’ disclosure of clinical trial results, according to a recent study from Bioethics International. Read More

The pharmaceutical industry is becoming more active in sharing clinical trial data in a way that may have seemed inconceivable 20 years ago, drugmakers said, even as it has taken heat for being opaque on disclosures. Read More

Results were mixed for drugmakers’ disclosure of clinical trial results, according to a new study from Bioethics International. Read More

Clinical trial patients are beginning to review their study sites on social media forums like Yelp, and one expert says sites should start thinking about how to manage their online reputations. Read More

When using social media to recruit trial participants with rare diseases, it is important for sponsors to earn their trust by sharing general disease and trial knowledge before pitching a specific trial, an expert says. Read More

Drugmakers are getting better at reporting clinical trials results in a timely manner, with only 10 percent of studies on new treatments approved by the European Medicines Agency in 2012 not disclosed within 12 months, a new study shows. Read More

Drugmakers are getting better at reporting clinical trials results in a timely manner, with only 10 percent of studies on new treatments approved by the European Medicines Agency in 2012 not disclosed within 12 months, a new study shows. Read More

The U.S. FDA’s device center is taking steps to improve the predictability of IDE reviews with the establishment of a new director-level position to oversee the clinical trials in the Office of Device Evaluation, a center official says. Read More